The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib

Purpose Sorafenib is an oral tyrosine kinase inhibitor (TKI) and first-line treatment option for advanced hepatocellular carcinoma (HCC). Preliminary evidence indicates proton pump inhibitors (PPI) may affect the absorption of TKIs through decreased gut dissolution. This study aims to evaluate the i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 2020-10, Vol.146 (10), p.2693-2697
Main Authors: Ruanglertboon, Warit, Sorich, Michael J., Logan, Jessica M., Rowland, Andrew, Hopkins, Ashley M.
Format: Article
Language:English
Subjects:
Cancer Research
Enzyme inhibitors
Hematology
Hepatocellular carcinoma
Internal Medicine
Liver cancer
Medicine
Medicine & Public Health
Oncology
Original Article – Clinical Oncology
Patients
Protein-tyrosine kinase
Proton pump inhibitors
Survival
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Sorafenib is an oral tyrosine kinase inhibitor (TKI) and first-line treatment option for advanced hepatocellular carcinoma (HCC). Preliminary evidence indicates proton pump inhibitors (PPI) may affect the absorption of TKIs through decreased gut dissolution. This study aims to evaluate the impact of PPI use on the survival outcomes of advanced HCC patients treated with sorafenib. Methods The study was a secondary analysis of individual-participant data from the phase III clinical trial NCT00699374. Cox proportional hazard analysis was used to evaluate the association between baseline PPI use and survival outcomes. Overall survival (OS) was the primary outcome with progression-free survival (PFS) secondary. Results In a cohort of 542 advanced HCC patients initiating sorafenib treatment, 122 were concomitantly using a PPI at baseline. No significant associations between baseline PPI use and OS were identified on univariable (HR [95% CI]; 1.01 [0.80–1.28], P  = 0.93) and adjusted (1.10 [0.82–1.41], P  = 0.62) analysis. Furthermore, no significant associations between baseline PPI use and PFS were identified on univariable (0.96 [0.76–1.21], P  = 0.73) and adjusted (1.11 [0.86–1.44], P  = 0.41) analysis. Conclusion In a large high-quality dataset, PPI use was not observed to compromise the survival outcomes of advanced HCC patients initiated on sorafenib.
ISSN:0171-5216
1432-1335
DOI:10.1007/s00432-020-03261-3